REG - Cambridge Cognition - Result of AGM & Change of Name of NOMAD & Broker

Cambridge Cognition HoldingsAnnouncement

28/06/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240628:nRSb4101Ua&default-theme=true

RNS Number : 4101U  Cambridge Cognition Holdings PLC  28 June 2024

28 June 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Result of AGM

Change of Name of Nominated Adviser and Joint Broker

 

Cambridge Cognition plc (AIM: COG), which develops and markets digital
solutions to assess brain health, held its Annual General Meeting ("AGM")
earlier today at the registered office of the Company; Tunbridge Court,
Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all
resolutions put forward were duly passed.

 

Proxy votes were received in respect of approximately 55% of the Company's
issued share capital and the votes cast were as follows:

 

 Resolution                                                                     For                 Against         Withheld
 1 - to approve the 2023 report and accounts                                    22,321,648  99.98%  5,003    0.02%  642,810
 2 - to appoint the auditors                                                    22,930,519  99.96%  8,503    0.04%  30,439
 3 - to authorise the directors to set the auditors remuneration                22,942,198  99.98%  5,003    0.02%  22,260
 4 - to re-elect Richard Bungay as a director                                   20,756,611  98.92%  226,842  1.08%  1,986,008
 5 - to elect Nick Rodgers as a director                                        22,927,961  99.82%  40,492   0.18%  1,008
 6 - to elect Stuart Gall as a director                                         22,927,961  99.82%  40,492   0.18%  1,008
 7 - authority to allot shares                                                  22,798,499  99.26%  169,954  0.74%  1,008
 8 - disapplication of pre-emption rights                                       22,789,981  99.22%  178,472  0.78%  1,008
 9 - disapplication of pre-emption rights in connection with an acquisition or  22,788,299  99.22%  180,154  0.78%  1,008
 specified capital investment

 

Change of Name of Nominated Adviser and Broker

 

The Company also announces that its Nominated Adviser and Joint Broker has
changed its name to Panmure Liberum Limited following completion of its own
corporate merger.

 

Enquiries

 

 Cambridge Cognition Holdings plc                          www.cambridgecognition.com (http://www.cambridgecognition.com/)
 Matthew Stork, Chief Executive Officer

 Stephen Symonds, Chief Financial Officer                  Tel: 01223 810 700

 Panmure Liberum Limited (NOMAD & Joint Broker)            Tel: 020 78862500
 Freddy Crossley / Emma Earl / Mark Rogers

 Rupert Dearden                                            (Corporate Advisory)

                                                           (Corporate Broking)
                                                           Tel: 020 3903 7715
 Dowgate Capital Limited (Joint Broker)

 David Poutney / James Serjeant                            (Corporate Broking)
 Hudson Sandler (Financial PR and IR)                      Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus

www.cambridgecognition.com (http://www.cambridgecognition.com/)

Tel: 01223 810 700

 

 Panmure Liberum Limited (NOMAD & Joint Broker)
 Freddy Crossley / Emma Earl / Mark Rogers
 Rupert Dearden

Tel: 020 78862500

(Corporate Advisory)

(Corporate Broking)

 Dowgate Capital Limited (Joint Broker)
 David Poutney / James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

Hudson Sandler (Financial PR and IR)

Dan de Belder / Hattie Dreyfus

Tel: 020 7796 4133

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company marketing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDZGZVZRNGDZM